Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
UCB SA (UCB)"UCB SA stock price live, this page displays EBR UCB stock exchange data. View the UCB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the UCB SA real time stock price chart below.
What Is the UCB SA Stock Price Today?
The UCB SA stock price today is 182.65.
What Is the Stock Symbol for UCB SA?
The stock symbol for UCB SA is ""UCB.""
What Stock Exchange Does UCB SA Trade On?
UCB SA is listed and trades on the Brussels stock exchange.
Is UCB SA a Good Stock to Buy?
Determining whether UCB SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the UCB quote. (ISIN: BE0003739530)"
What Is the UCB SA Stock Price Today?
The UCB SA stock price today is 182.65.
What Is the Stock Symbol for UCB SA?
The stock symbol for UCB SA is ""UCB.""
What Stock Exchange Does UCB SA Trade On?
UCB SA is listed and trades on the Brussels stock exchange.
Is UCB SA a Good Stock to Buy?
Determining whether UCB SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the UCB quote. (ISIN: BE0003739530)"
182.65
-1.55(-0.84%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
181.45
182.65
52 wk Range
73.14
189.05
UCB Scorecard
Full Analysis
Has raised its dividend for 15 consecutive years
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
181.45182.65
52 wk Range
73.14189.05
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.52%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.52%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
UCB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
192.69
Upside
+6.66%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ucb receives Investment Bank Analyst Rating Update
- Investing.com
Pro
UCB SA Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; minzasolmin and UCB0222 for Parkinson’s disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Compare UCB to Peers and Sector
Metrics to compare | UCB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipUCBPeersSector | |
|---|---|---|---|---|
P/E Ratio | 143.6x | 20.8x | −0.6x | |
PEG Ratio | −5.20 | 0.14 | 0.00 | |
Price/Book | 3.9x | 3.5x | 2.6x | |
Price / LTM Sales | 6.3x | 2.4x | 3.2x | |
Upside (Analyst Target) | - | 17.4% | 49.4% | |
Fair Value Upside | Unlock | 10.7% | 7.8% | Unlock |
Dividends
Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.26
Dividend Yield
0.52%
Industry Median 2.22%
Annualised payout
0.9520
Paid annually
5-Years Growth
+2.36%
Growth Streak
FAQ
What Is the UCB (UCB) Stock Price Today?
The UCB stock price today is 182.65
What Stock Exchange Does UCB Trade On?
UCB is listed and trades on the Vienna stock exchange.
What Is the Stock Symbol for UCB?
The stock symbol for UCB is "UCB."
Does UCB Pay Dividends? What’s The Current Dividend Yield?
The UCB SA dividend yield is 0.52%.
What Is the UCB Market Cap?
As of today, UCB market cap is 34.27B.
What is UCB Earnings Per Share?
The UCB EPS is 1.26.
What Is the Next UCB Earnings Date?
UCB will release its next earnings report on 26 Feb 2025.
From a Technical Analysis Perspective, Is UCB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.